{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:41:47Z","timestamp":1792899707714,"version":"4.5.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the malignancies with the highest mortality rates, and outcomes are particularly poor in cases of liver metastasis. Early or recurrent metastatic PDAC significantly worsens patient outcomes and presents substantial clinical challenges. Checkpoint-based immunotherapy has largely been ineffective for most pancreatic cancer patients. This ineffectiveness is not well understood, as clinical trials often involve patients with advanced diseases, such as liver and peritoneal metastases, while most preclinical studies focus on primary tumors. Recent findings indicate that the immunosuppressive tumor microenvironment (TME) is a major obstacle to effective immunotherapy in PDAC, with the metastatic immune microenvironment differing significantly from that of primary tumors. This review explores the distinct immunosuppressive mechanisms at various stages of PDAC progression, including primary tumors, pre-metastatic niches, and metastatic sites. Myeloid cells, such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), play pivotal roles in shaping the TME and suppressing anti-tumor immunity. Particular focus is placed on current clinical immunotherapy strategies targeting myeloid cells, and combinations with conventional chemoradiotherapy, considering contemporary knowledge and future trends. Advancements in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics have provided deeper insights into the molecular intricacies and diversity of PDAC, revealing potential therapeutic targets. Innovative strategies targeting myeloid cells, including CD40 agonists and CSF-1R inhibitors, are being explored to reprogram the TME and enhance the efficacy of immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1555036","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T01:21:42Z","timestamp":1747358502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting myeloid cells in pancreatic ductal adenocarcinoma: from primary tumors to liver metastasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruining","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11579-0","article-title":"Recurrence after resection of pancreatic cancer: can radiomics predict patients at greatest risk of liver metastasis","volume":"29","author":"Zambirinis","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02272","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"41","author":"Topalian","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02270","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13014-020-01569-5","article-title":"The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database","volume":"15","author":"Amin","year":"2020","journal-title":"Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9240","article-title":"Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies","volume":"11","author":"Panni","year":"2019","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s43018-022-00500-z","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13046-021-02019-0","article-title":"C4b-binding protein \u03b1-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer","volume":"40","author":"Sasaki","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.049","article-title":"The basis of oncoimmunology","volume":"164","author":"Palucka","year":"2016","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06685-2","article-title":"IL-1\u03b2+ macrophages fuel pathogenic inflammation in pancreatic cancer","volume":"623","author":"Caronni","year":"2023","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature13989","article-title":"Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors","volume":"518","author":"Gomez Perdiguero","year":"2015","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204351","article-title":"Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation","volume":"332","author":"Jenkins","year":"2011","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ni.3341","article-title":"The development and maintenance of resident macrophages","volume":"17","author":"Perdiguero","year":"2016","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin","year":"2014","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.immuni.2017.07.014","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0322","article-title":"T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma","volume":"5","author":"Stromnes","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.131","article-title":"CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype","volume":"23","author":"Candido","year":"2018","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001460","article-title":"Rethinking immune checkpoint blockade: \u2018Beyond the T cell\u2019","volume":"9","author":"Liu","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.80721","article-title":"Arginase 1 is a key driver of immune suppression in pancreatic cancer","volume":"12","author":"Menjivar","year":"2023","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003005","article-title":"GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors","volume":"9","author":"DeNardo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"103315","DOI":"10.1016\/j.ebiom.2021.103315","article-title":"Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma Malignant progression","volume":"66","author":"Chen","year":"2021","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1038\/s41467-023-40895-6","article-title":"Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype","volume":"14","author":"Oh","year":"2023","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01157-1","article-title":"Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer","volume":"54","author":"Cui Zhou","year":"2022","journal-title":"Nat Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"104430","DOI":"10.1016\/j.critrevonc.2024.104430","article-title":"Spatial transcriptomics in pancreatic cancer: Advances, prospects and challenges","volume":"203","author":"Li","year":"2024","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13073-024-01287-7","article-title":"Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis","volume":"16","author":"Kim","year":"2024","journal-title":"Genome Medicine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.smim.2016.01.002","article-title":"Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment","volume":"28","author":"Arina","year":"2016","journal-title":"Semin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune suppressive mechanisms in the tumor microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01914-4","article-title":"Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity","volume":"56","author":"Khaliq","year":"2024","journal-title":"Nat Genet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1016\/j.cell.2021.09.022","article-title":"Spatially confined sub-tumor microenvironments in pancreatic cancer","volume":"184","author":"Gr\u00fcnwald","year":"2021","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","article-title":"Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer","volume":"184","author":"Raghavan","year":"2021","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the pre-metastatic niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41467-020-20447-y","article-title":"Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0271-z","article-title":"Immune crosstalk in cancer progression and metastatic spread: a complex conversation","volume":"20","author":"Garner","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3169","article-title":"Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver","volume":"17","author":"Costa-Silva","year":"2015","journal-title":"Nat Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1053\/j.gastro.2016.07.043","article-title":"Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1, which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver","volume":"151","author":"Gr\u00fcnwald","year":"2016","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27378","article-title":"Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1\/CXCR4-dependent neutrophil recruitment in mice","volume":"61","author":"Seubert","year":"2015","journal-title":"Hepatology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"12819","DOI":"10.1038\/ncomms12819","article-title":"Metastatic progression is associated with dynamic changes in the local microenvironment","volume":"7","author":"Aiello","year":"2016","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0909607","article-title":"Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor","volume":"87","author":"Connolly","year":"2010","journal-title":"J Leukoc Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.3390\/cancers14123028","article-title":"The liver pre-metastatic niche in pancreatic cancer: A potential opportunity for intervention","volume":"14","author":"Gumberger","year":"2022","journal-title":"Cancers"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-015-1376-x","article-title":"Immunosuppressive cells in tumor immune escape and metastasis","volume":"94","author":"Liu","year":"2016","journal-title":"J Mol Medicine"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3015","article-title":"The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis","volume":"16","author":"McAllister","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06114-4","article-title":"Tumour extracellular vesicles and particles induce liver metabolic dysfunction","volume":"618","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03075-7","article-title":"Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer","volume":"30","author":"Bojmar","year":"2024","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13059-020-02222-w","article-title":"Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma","volume":"22","author":"Yang","year":"2021","journal-title":"Genome Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00731-2","article-title":"Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis","volume":"5","author":"Astuti","year":"2024","journal-title":"Nat Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41368-021-00146-0","article-title":"From bulk, single-cell to spatial RNA sequencing","volume":"13","author":"Li","year":"2021","journal-title":"Int J  Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0195-y","article-title":"Single-cell RNA-seq highlights intra-tumoral heterogeneity and Malignant progression in pancreatic ductal adenocarcinoma","volume":"29","author":"Peng","year":"2019","journal-title":"Cell Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01134-8","article-title":"Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment","volume":"54","author":"Hwang","year":"2022","journal-title":"Nat Genet"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1038\/s41467-023-40727-7","article-title":"Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41698-023-00455-z","article-title":"High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival","volume":"7","author":"Storrs","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-021-00271-4","article-title":"Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response","volume":"7","author":"Wang","year":"2021","journal-title":"Cell Discov"},{"key":"B73","doi-asserted-by":"publisher","first-page":"110609","DOI":"10.1016\/j.celrep.2022.110609","article-title":"Metabolism drives macrophage heterogeneity in the tumor microenvironment","volume":"39","author":"Li","year":"2022","journal-title":"Cell Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/mog.v1.1","article-title":"Tumor immunotherapy: Mechanisms and clinical applications","volume":"1","author":"Nong","year":"2022","journal-title":"MedComm \u2013 Oncology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"216726","DOI":"10.1016\/j.canlet.2024.216726","article-title":"PD-1 regulation in immune homeostasis and immunotherapy","volume":"588","author":"Gao","year":"2024","journal-title":"Cancer Letters"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Nevala-Plagemann","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/gutjnl-2018-317570","article-title":"Stromal protein \u03b2ig-h3 reprogrammes tumour microenvironment in pancreatic cancer","volume":"68","author":"Goehrig","year":"2019","journal-title":"Gut"},{"key":"B78","doi-asserted-by":"publisher","first-page":"217350","DOI":"10.1016\/j.canlet.2024.217350","article-title":"Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy","volume":"610","author":"Yu","year":"2025","journal-title":"Cancer Letters"},{"key":"B79","doi-asserted-by":"publisher","first-page":"217289","DOI":"10.1016\/j.canlet.2024.217289","article-title":"Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment","volume":"605","author":"Zhang","year":"2024","journal-title":"Cancer Letters"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Medicine"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3876","article-title":"Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer","volume":"78","author":"Quaranta","year":"2018","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2212","article-title":"An immunosuppressive dendritic cell subset accumulates at secondary sites and promotes metastasis in pancreatic cancer","volume":"77","author":"Kenkel","year":"2017","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3340","article-title":"Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat Cell Biol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.03.011","article-title":"Distant relations: macrophage functions in the metastatic niche","volume":"4","author":"Doak","year":"2018","journal-title":"Trends Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00836-2","article-title":"Locally sourced: site-specific immune barriers to metastasis","volume":"23","author":"Correia","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","article-title":"In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases","volume":"41","author":"Kerzel","year":"2023","journal-title":"Cancer Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1032","article-title":"IFN\u03b3 and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma","volume":"6","author":"Long","year":"2016","journal-title":"Cancer Discov"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005425","article-title":"Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma","volume":"11","author":"Sinha","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.v3.1","article-title":"Targets of tumor microenvironment for potential drug development","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm \u2013 Oncology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v145.5","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid Malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"Int J Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O'Hara","year":"2021","journal-title":"Lancet Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","article-title":"A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors","volume":"41","author":"Moreno","year":"2023","journal-title":"Invest New Drugs"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/1538-7445.AM2024-2376","article-title":"Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model","volume":"84","author":"Smith","year":"2024","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT134","article-title":"Safety and immunologic impact of neoadjuvant\/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma","volume":"84","author":"Arielle Urman","year":"2024","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Invest New Drugs"},{"key":"B110","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.070","article-title":"Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study","volume":"32","author":"Tempero","year":"2021","journal-title":"Ann Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1555036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:05:12Z","timestamp":1747631112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1555036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":114,"alternative-id":["10.3389\/fimmu.2025.1555036"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1555036","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1555036"}}